TIGIT interacts with its ligands, CD155 (PVR) and CD112 (Nectin-2), which are often overexpressed on tumor cells and antigen-presenting cells (APCs) within the TME (Gorvel and Olive, 2020; Jo et al., 2024). Here, NECTIN2 is linked to neoplasm.